Jarrett Jennifer 4
4 · Arcus Biosciences, Inc. · Filed Oct 8, 2025
Insider Transaction Report
Form 4
Jarrett Jennifer
Chief Operating Officer
Transactions
- Sale
Common Stock
2025-10-06$14.54/sh−12,500$181,801→ 214,232 total - Sale
Common Stock
2025-10-08$15.05/sh−37,792$568,611→ 214,232 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−37,792→ 130,874 totalExercise: $1.23Exp: 2027-03-14→ Common Stock (37,792 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-06−12,500→ 168,666 totalExercise: $1.23Exp: 2027-03-14→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2025-10-06$1.23/sh+12,500$15,345→ 226,732 total - Exercise/Conversion
Common Stock
2025-10-08$1.23/sh+37,792$46,393→ 252,024 total
Footnotes (5)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The option is fully vested and currently exercisable.